The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...
The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.
Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...
New medication that can cut body weight by 23% could radically reduce the number of people who are obese. Tirzepatide is ...
Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcoholism, a new study suggests. Researchers explain why diabetes and weight loss drugs work better than alcohol medications.
In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...
Eli Lilly and Co. (LLY) has released detailed findings from the Phase 3 SUMMIT trial, demonstrating that tirzepatide significantly ...
HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...
CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...
The improved engagement with HF patients intended to optimize GDMT was very modest, but did lead to increased use of MRAs.
Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...
A new study has found that the groundbreaking new class of weight loss drugs may not only be good at treating diabetes, but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback